Bristol Myers Squibb just smashed Q2 earnings with $12.97 billion in revenue—way above forecasts—and bumped up its full-year outlook to $49.5 billion. Strong EPS and explosive growth from its “growth portfolio” drugs like Reblozyl, Breyanzi, and Camzyos are driving the momentum, while stalwarts like Eliquis keep the ship steady amid generic threats. The company’s future is bright: AI-powered drug discovery partnerships with NVIDIA, promising trials for pulmonary fibrosis and multiple myeloma, and a slight uptick in R&D spending to fuel upcoming launches. With disciplined execution and a laser focus on oncology and cardiology, BMS is clearly building for sustained, high-velocity growth.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
